Gestala Highlights Rapid Funding, Chengdu-Centered Growth and Hiring in NeuroAI and BCI

According to a recent LinkedIn post from Gestala, the Chengdu-based NeuroAI and brain-computer interface startup is emphasizing its rapid early-stage progress and recruitment plans. The post indicates Gestala was launched on January 1 and portrays the company as China’s first ultrasound-based BCI player, reporting that it raised about ¥150M (over $20M) in Angel funding within two months.

The company’s LinkedIn post highlights a strategy centered on Chengdu as a base for long-term growth in BCI and NeuroAI. The post points to proximity to West China Hospital, a biotech and hardware cluster in the Chengdu Hi-Tech Zone, and the city’s quality-of-life attributes as key elements of what it describes as an enabling ecosystem.

As shared in the post, Gestala is seeking to expand its headcount to more than 40 employees by year-end, with hiring focused on scientific research, engineering, and artificial intelligence. Priority areas include cognitive and computational neuroscience, clinical medicine, electronics and chip design, and AI domains such as multimodal models and machine-learning algorithms for NeuroAI.

For investors, the reported Angel round size and hiring ambitions suggest an aggressive early build-out that may accelerate technology development but also increase cash burn. If Gestala’s ultrasound-based BCI approach proves technically and clinically viable, the combination of strong medical partnerships and Chengdu’s cost and talent advantages could strengthen its competitive position in China’s emerging NeuroAI and BCI market.

The post’s emphasis on Chengdu’s GDP scale, infrastructure, and international connectivity also implies a bet that the city can support globally oriented deep-tech companies. This geographic positioning, if successful, may enable Gestala to balance access to clinical resources and hardware supply chains with potentially lower operating costs than more established tech hubs, which could be relevant to future funding and valuation discussions.